Insulet Redefines Diabetes at CES with "Liveable Technology" — A New Frontier in Human-Centered Connected Health

Key Terms

automated insulin delivery system medical

An automated insulin delivery system is a device that automatically monitors blood sugar levels and adjusts insulin delivery without needing manual input. Think of it as a smart thermostat that keeps a room’s temperature just right, ensuring stable levels. For investors, such systems represent advances in healthcare technology that can improve quality of life and potentially reduce long-term medical costs.

connected health technical

Connected health is the use of digital tools—such as sensors, smartphone apps, telemedicine, and cloud platforms—to collect, share and manage a person’s health information across providers and devices. For investors it matters because these systems can lower healthcare costs, create recurring-service revenue, and scale patient access much like a smart home network turns separate devices into a coordinated system; adoption, data security and regulation drive the financial risks and rewards.

• The Company will host a Digital Health Track panel discussion exploring how human-first design and intelligent automation are transforming chronic care into everyday freedom
• Insulet’s immersive booth will showcase how tubeless, automated insulin delivery transforms the lives of people with diabetes by reducing mental load and improving health outcomes

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod^® brand of products, today announced its debut at Consumer Electronics Show (CES) 2026, where the Company will showcase its vision for liveable technology through an immersive booth experience, expert panel session, and media demonstrations.

Liveable technology reflects Insulet’s philosophy for the future of connected health: effortless, intelligent systems that support daily life. As digital health accelerates, people increasingly want technology that lightens the mental load and surfaces insights only when they matter. At CES, Insulet will demonstrate a bold vision for liveable technology—intuitive and adaptive solutions that fit naturally into life. The Company will offer an immersive experience demonstrating how Omnipod makes connected health simple and empowering.

“CES is where the future of technology takes shape, and Insulet is proud to help bring the voice of those living with diabetes into that future,” said Manoj Raghunandanan, Chief Growth Officer at Insulet. “Each day brings dozens of choices that can be tiring and complex for anyone managing diabetes. Our goal is to ease that burden by creating technology that fits naturally into life. Omnipod reflects that vision of liveable technology, progress that helps people feel supported and more in control. By innovating at the nexus of MedTech, healthcare, and consumer, we’re showing that real change happens when life and technology actually work together.”

Showcasing liveable technology across CES 2026

For people with type 1 or insulin-intensive type 2 diabetes, keeping blood glucose levels in a safe range is time-consuming and mentally exhausting. Throughout the show, Insulet will highlight how Omnipod 5, the tubeless automated insulin delivery system, embodies liveable technology by helping people manage their diabetes through trustworthy automation that works seamlessly in the background.

Key elements of Insulet’s CES 2026 presence include:

Featured Panel: “The Rise of Liveable Tech: Calm, Intelligent, and Human-First"

Insulet will host a dynamic conversation that explores new possibilities for the future of connected health. This CES panel brings together innovators, clinicians, and real-world voices to explore how connected health is evolving toward insight-driven, emotionally supportive systems that reduce cognitive burden for people with chronic conditions. Learn more here.

• When: January 6, 3:25 PM - 4:05 PM PT
• Where: Venetian, Level 4, Marcello 4404

Interactive Booth Experience featuring Omnipod

Visitors will discover what “liveable technology” really means by immersing themselves in the Omnipod experience at CES. The Insulet booth will offer a hands-on journey into how automation and human-first design can make life with diabetes simpler and more empowering. Attendees will have the opportunity to connect with product specialists, hear inspiring stories from individuals living with diabetes, and preview innovations shaping the next era of connected health. The Insulet team will be located at the Venetian Expo, Level 2, Booth #54412—offering a gateway to a future where technology integrates seamlessly into everyday life.

About Omnipod 5

Integrated with a continuous glucose monitor, Omnipod 5 helps users spend less time thinking about diabetes and more time living their lives. The system delivers personalized, automated insulin delivery without tubing, fingersticks, or multiple daily injections, exemplifying Insulet’s commitment to calm, human-centered innovation at the intersection of consumer experience, advanced technology, and healthcare.

For more information about Insulet at CES 2026, including ongoing coverage from the show floor, follow the company on LinkedIn, Instagram, Facebook, and X.

About Insulet Corporation

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: insulet.com and omnipod.com.

©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260106462689/en/

Investor Relations:

Clare Trachtman

Vice President, Investor Relations

ir@insulet.com

Media:

Angela Geryak Wiczek

Senior Director, Corporate Communications

pr@insulet.com

Source: Insulet Corporation